Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs

Formation Bio launches $600M fund to accelerate AI-powered drug development - Tech Startups

Formation Bio is launching a $600 million investment fund to acquire promising experimental medicines and move them through clinical trials faster using artificial intelligence. The New York-based biotech company is betting that the pharmaceutical industry’s biggest problem isn’t finding new […] The post Formation Bio launches $600M fund to accelerate AI-powered drug development first appeared on Tech Startups.

Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs

Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.

Formation Bio launches $600m drug development fund

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

Formation Bio Launches $600M Drug Development Fund to Expand Clinical-Stage Pipeline

Formation Bio, a New York-based pharmaceutical company using artificial intelligence to accelerate drug development, has launched the Formation Bio Drug... The post Formation Bio Launches $600M Drug Development Fund to Expand Clinical-Stage Pipeline appeared first on citybiz.

Formation Bio unveils $600M fund to license and test more drugs

Formation Bio, an AI-focused biotech that acquires outside assets, develops them and then hands them off, has raised a $600 million investment found to double down on that strategy. The new fund will help it ...